Candice Long is the Worldwide Vice President for the Immunology Therapeutic Area with Johnson & Johnson Innovative Medicine. Together with the Immunology Research & Development Therapeutic Area leader, she has end-to-end responsibility for the Immunology portfolio and pipeline, leading global commercial efforts to build and maximize value in areas of high unmet need.
In her former role as U.S. President, Infectious Diseases & Vaccines (ID&V), Candice was responsible for steering the ID&V business to deliver on near- and long-term growth objectives to advance Janssen’s HIV portfolio, strengthening organizational readiness to introduce vaccines, and leading ongoing efforts to expand the breadth of the business.
Prior to that role, Candice was Vice President of Marketing for U.S. Immunology. During her time with Immunology, business grew significantly with the successful launch of TREMFYA® (guselkumab) for psoriasis and STELARA® (ustekinumab) for ulcerative colitis, with increased focus on fulfillment through new support services while effectively protecting patients’ ability to maintain success on their STELARA and REMICADE® (infliximab) treatments. Candice began her career at Johnson & Johnson and has held various other roles with increasing responsibilities in the Pharmaceuticals and Consumer sectors.
Passionate about digital innovation and advocacy in healthcare, Candice has also served as the Executive Sponsor of Janssen Cares, a comprehensive employee giving program. In addition, she served as an Executive Sponsor of the Company’s Employee Resource Group, Open&Out, a global network of LGBTQ+ and Ally individuals who seek to make a difference by creating safe and inclusive workspaces, fostering healthier communities, and empowering employees.
She earned an MBA from the College of William & Mary in Williamsburg, Virginia, and received a Bachelor of Science in Business Administration and Bachelor of Arts in History from Mary Washington College in Fredericksburg, Virginia.
Follow Candice on LinkedIn here.